Nasdaq:US$13.90 (-1.11) | HKEX:HK$21.25 (-2.30) | AIM:£2.28 (-0.24)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
1
2
找到相關結果： 88
科學出版物 | 2024-09-11

《柳葉刀 · 呼吸醫學》：賽沃替尼一綫治療 MET 外顯子14跳變 非小細胞肺癌的IIIb 期確證性研究結果
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
閱讀更多
科學出版物 | 2024-06-17

《柳葉刀 · 血液病學》: 索樂匹尼布用于治療中國成人原發免疫性血小板减少症患者的ESLIM-01研究：一項隨機、隨機、雙盲、安慰劑對照的III期研究
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study Yu Hu*, Xiaofan Liu*, Hu Zhou*, Shujie Wang, Ruibin Hua
閱讀更多
科學出版物 | 2024-06-03

《自然ž·醫學 (Nature Medicine)》: 呋喹替尼與紫杉醇聯合療法用於二線治療晚期胃癌 FRUTIGA 中國III 期研究
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial Feng Wang, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen,
閱讀更多
科學出版物 | 2024-05-07

Cancer Immunology, Immunotherapy: Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer   Panpan Zhang, Zhendon
閱讀更多
公告及新聞稿, 科學出版物 | 2024-04-18

ACS Medicinal Chemistry Letters: Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers
Hong Jia, Wei Deng, Baoyu Hao, Min Cai, Dong Guo, Yu Cai, Xiaoming Dai, Zhipeng Wu, Weigang He, Jian Wang, Guanglin Wang, Sumei Xia, Na Li, Weiguo Su, and Guangxiu Dai*         Abstract Herein we describe the med
閱讀更多
科學出版物 | 2024-01-15

European Journal of Cancer: Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial   Panpan Zhang, Si Shi, Jianming Xu, Zhendong Chen, Lijie Song, Xing Zhan
閱讀更多
科學出版物 | 2023-06-16

《柳葉刀 (The Lancet)》: 呋喹替尼治療經治轉移性結直腸癌的FRESCO-2 III期研究
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study Arvind Dasari*, Sara Lonardi*, Rocio Garcia-Carbonero, Elena Elez, Takayuki
閱讀更多
科學出版物 | 2023-04-05

《柳葉刀 · 血液病學》：索樂匹尼布用于治療中國原發免疫性血小板減少症患者
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study Xiaofan Liu, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang
閱讀更多
科學出版物 | 2023-03-17

JSMO2023: 呋喹替尼治療日本難治性轉移性結直腸癌患者
The outcome for patients in Japan from the FRESCO-2 multi-regional clinical trial of fruquintinib, an oral inhibitor of VEGFR-1, -2 and -3, are being presented at the 2023 Japanese Society of Medical Oncology Annual Meeting, taking place March 16-18
閱讀更多
科學出版物 | 2023-01-09

European Journal of Cancer: Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases   Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, We
閱讀更多
科學出版物 | 2022-09-12

ESMO2022: FRESCO-2研究: 一項旨在評估呋喹替尼用於治療難治性轉移性結直腸癌患者的療效和安全性的全球 III 期國際多中心臨床試驗
標題： FRESCO-2: A global Phase 3 multi-regional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer FRESCO-2研究: 一項旨在評估呋喹替尼用於治
閱讀更多
科學出版物 | 2022-06-06

ASCO2022: 索凡替尼在美國軟組織肉瘤患者中的應用
Surufatinib in U.S. patients with soft tissue sarcoma   Authors Sujana Movva, Alexander I. Spira, Erika P. Hamilton, Judy S. Wang, Allen Lee Cohn, James F. Strauss, Silvia Stacchiotti, Chris Tucci, John Kauh, Shivani Nanda, Marek K. Kania, Sh
閱讀更多
科學出版物 | 2022-06-06

ASCO2022: 兩項 Ⅲ 期臨床試驗中索凡替尼治療晚期 NETs 患者的安全性匯總分析
A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs   Authors Jie Li, Jianming Xu, Lin Shen, Chunmei Bai, Zhiwei Zhou, Zhiping Li, Yihebali Chi, Xianjun Yu, Enxiao LI, Nong Xu, Tianshu Liu, Wenhui Lou, Yuxian Bai, Xia
閱讀更多
科學出版物 | 2021-12-12

ASH 2021: 選擇性口服Syk抑制劑HMPL-523治療復發或難治性淋巴瘤患者的I期臨床試驗初步結果
查看海報 (PDF)
科學出版物 | 2021-11-03

NANETS 2021: 索凡替尼治療美國神經內分泌瘤患者的中期分析結果
查看海報 (PDF)
科學出版物 | 2021-09-17

ESMO 2021：呋喹替尼與替雷利珠單抗聯合療法治療晚期三陰性乳腺癌患者的Ib/II期研究
標題: An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple negative breast cancer 一項評估呋喹替尼與替雷利珠單抗聯合療法治
閱讀更多
查看海報 (PDF)
演示文稿, 科學出版物 | 2021-06-22

《刺針 · 呼吸醫學》：賽沃替尼治療MET外顯子14 跳躍突變的中國非小細胞肺癌患者
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study   Shun Lu, Jian Fang
閱讀更多
科學出版物 | 2021-06-04

ASCO 2021: 多中心、開放標簽的I期研究︰評估HMPL-306治療伴有IDH突變的局部晚期或轉移性實體瘤患者的安全性和耐受性
標題: A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations. 一項多中心、開放標簽的I期研究︰評估HMPL-30
閱讀更多
查看海報 (PDF)
科學出版物 | 2021-06-04

ASCO 2021: 索凡替尼聯合替雷利珠單抗治療晚期實體瘤患者的開放標簽的Ib/II期臨床研究
標題: An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors 索凡替尼聯合替雷利珠單抗治療晚期實體瘤患者的開放標簽的Ib/II期臨床研究 主
閱讀更多
查看海報 (PDF)
科學出版物 | 2021-06-04

ASCO 2021: 索凡替尼治療美國神經內分泌瘤患者的中期分析結果
標題: Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs). 索凡替尼治療美國神經內分泌瘤患者的中期分析結果 主要作者: Scott Paulson, MD, Baylor Sammons Cancer Center
閱讀更多
查看海報 (PDF)
科學出版物 | 2021-04-09

AACR 2021: 賽沃替尼在伴有MET外顯子14跳變的NSCLC患者中的II期研究的ctDNA分析
AACR 2021: ctDNA Analysis in the Savolitinib Phase II Study in NSCLC Patients Harboring METex14 Skipping Alterations Presenter/Authors: Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, 
閱讀更多
查看海報 (PDF)
演示文稿, 科學出版物 | 2021-03-04

ASCO-GI 2021: FRESCO-2 呋喹替尼國際III期結直腸癌研究
FRESCO-2: A global phase 3 study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC) Arvind Dasari, James Yao, Alberto Sobrero, Takayuki Yoshino, William Schelman, Shivani Nanda, Caly Chien, Su-Fen
閱讀更多
查看海報 (PDF)
演示文稿, 科學出版物 | 2020-12-05

ASH2020: 選擇性口服PI3Kδ抑制劑HMPL-689治療中國復發/難治性淋巴瘤患者的I期劑量遞增研究結果
標題： Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with relapsed/refractory (R/R) Lymphoma 選擇性口服磷脂醯肌醇3-激酶亞型δ
閱讀更多
查看摘要 (PDF)下載演示文稿 (PDF)
演示文稿, 科學出版物 | 2020-09-21

《刺針·腫瘤學》：索凡替尼SANET-p III期研究
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe
閱讀更多
演示文稿, 科學出版物 | 2020-09-21

《刺針·腫瘤學》：索凡替尼SANET-ep III期研究
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T
閱讀更多
演示文稿, 科學出版物 | 2020-09-20

ESMO2020: 索凡替尼治療晚期胰腺神經內分泌瘤患者（SANET-p）
標題： 索凡替尼治療晚期胰腺神經內分泌瘤患者（SANET-p）：隨機、雙盲、安慰劑對照的III期臨床試驗 (NCT02589821) 主要作者： 中國人民解放軍總醫院第五醫學中心 消化腫瘤科主任
閱讀更多
下載演示文稿 (PDF)
演示文稿, 科學出版物 | 2020-09-18

ESMO2020: 呋喹替尼治療晚期實體瘤患者的I/Ib期臨床試驗
標題： 呋喹替尼治療晚期實體瘤患者的I/Ib期臨床試驗：難治性轉移性結直腸癌劑量遞增佇列的初步結果 會議環節： N. Arvind Dasari, Associate Professor, Department of Gastrointestinal (GI) Medical
閱讀更多
下載海報（PDF）
演示文稿, 科學出版物 | 2020-09-18

ESMO2020: 索凡替尼SANET-ep研究按Ki-67和原發腫瘤起源的亞組分析
標題： 索凡替尼治療晚期高分化的非胰腺神經內分泌瘤的隨機、安慰劑對照的III期臨床試驗（SANET-ep）按Ki-67和原發腫瘤起源的亞組分析 主要作者： 中山大學腫瘤防治中心 胃胰科
閱讀更多
下載海報（PDF）
演示文稿, 科學出版物 | 2020-04-27

AACR2020: 索凡替尼在中美患者中的藥代動力學特征及安全性比較
標題： 索凡替尼在中美患者中的藥代動力學特征及安全性比較 報告人： Arvind Dasari 作者： A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K Li7, C Chien7, J Kauh7, M Kani
閱讀更多
下載演示文稿 (PDF)
演示文稿, 科學出版物 | 2020-04-27

AACR2020: 關於索凡替尼聯合特瑞普利單抗治療晚期實體瘤患者的I期臨床研究
標題： 關於索凡替尼聯合特瑞普利單抗治療晚期實體瘤患者的I期臨床研究 報告人： 曹彥碩 作者： 陸明1, 曹彥碩1, 龔繼芳1, 孫宇2, 李潔1, 沈琳1. 1北京大學腫瘤醫院惡性腫
閱讀更多
下載演示文稿 (PDF)
演示文稿, 科學出版物 | 2020-03-13

ENETS 2020 : 索凡替尼用於中國晚期非胰腺神經內分泌瘤患者的安全性和特殊不良事件：SANET-ep研究數據分析
>> 相關報道 The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-panc
閱讀更多
下載海報
演示文稿, 科學出版物 | 2020-02-06

《刺針·腫瘤學》奧希替尼與沃利替尼用于EGFR突變、MET擴增的非小細胞肺癌
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;
閱讀更多
演示文稿, 科學出版物 | 2019-09-29

ESMO 2019: 索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性
標題： 索凡替尼用於治療高分化的晚期非胰腺神經內分泌瘤患者的療效和安全性：隨機化的III期臨床試驗（SANET-ep）結果 報告人： 中國人民解放軍總醫院第五醫學中心 消化腫瘤科
閱讀更多
演示文稿, 科學出版物 | 2019-09-21

CSCO 2019: FRESCO研究中手足皮膚反應的發生情況及與療效的關係
報告 FRESCO 研究中手足皮膚反應的發生情況及與療效的關係 報告人： 白玉賢，哈爾濱醫科大學附屬腫瘤醫院 其他作者： 李進 ，秦叔逵 ，徐瑞華，沈琳，徐建明，鄧豔紅，楊
閱讀更多
演示文稿, 科學出版物 | 2019-09-19

CSCO 2019 : 呋喹替尼三線治療中國轉移性結直腸癌的III期臨床研究（FRESCO）中的肝轉移亞組分析
報告 呋喹替尼三線治療中國轉移性結直腸癌的III 期臨床研究（FRESCO）中的肝轉移亞組分析 報告人： 秦叔逵，東部戰區總醫院（原八一醫院） 其他作者： 李進，徐瑞華，沈琳
閱讀更多
演示文稿, 科學出版物 | 2019-09-09

WCLC 2019: 呋喹替尼治療晚期非小細胞肺癌（FALUCA）III期試驗
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
閱讀更多
Download Presentation (PDF)
演示文稿, 科學出版物 | 2019-06-01

《Clinical Cancer Research》：索凡替尼在高分化神經內分泌瘤的使用
Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao
閱讀更多
演示文稿, 科學出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
閱讀更多
演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
閱讀更多
演示文稿, 科學出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
閱讀更多
演示文稿, 科學出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
閱讀更多
演示文稿, 科學出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
閱讀更多
演示文稿, 科學出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
閱讀更多
演示文稿, 科學出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
閱讀更多
演示文稿, 科學出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
閱讀更多
演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
閱讀更多
演示文稿, 科學出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
閱讀更多
演示文稿, 科學出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
閱讀更多
演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
閱讀更多
演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
閱讀更多
1
2